While many hospitals have implemented initiatives resulting in 10-20% reductions in blood utilization, most are unable to quantify their true remaining clinical and financial opportunity due to a lack of accurate, meaningful benchmarks and assessment tools. As the saying goes, “if you can’t measure it, you can’t improve it”.

CLINICAL AND FINANCIAL OPPORTUNITY

An estimated 20-40% of all blood product transfusions remain unnecessary, excessive or avoidable contributing to:

Millions of patients exposed every year to avoidable blood transfusions leading to thousands of serious transfusion-related adverse events

Excessive utilization of a scarce resource, contributing to critical blood shortages

Billions of dollars in wasted healthcare costs every year

WHY CHOOSE ACCUMEN FOR BENCHMARKING

  • Non-disruptive process and small data ask (no IT needs)
  • Requires 2-4 hours of hospital time
  • No risk, obligation-free discussions
  • Complimentary benchmarking available for qualifying
    organizations

REQUEST A DIAGNOSTIC & OVERVIEW (PDF)



What’s your opportunity to improve patient safety and reduce cost?

See if your hospital qualifies for a complimentary Benchmarking &
Diagnostic Analysis for Patient Blood Management.

 

WHAT IS INCLUDED IN OUR ANALYSIS?

QUALITATIVE COMPONENTS

  • PBM program infrastructure and executive/ clinical engagement
  • Current transfusion practice compared to Accumen best-in-class transfusion guidelines
  • Current CPOE/clinical decision support capabilities for transfusion ordering
  • Current PBM/transfusion metrics, reports, and goals
  • Education and awareness campaign strategy
  • Evaluation of proactive strategies to improve patient outcomes (including anemia management and strategies to minimize bleeding and blood loss)

QUANTITATIVE COMPONENTS

  • 500+ hospitals within the PBM dataset representing a wide range of organizations
  • Comparison to like hospitals with active PBM Programs based on multiple attributes (e.g., bed size, specialty mix, etc.)
  • Multiple benchmarks used to quantify opportunity (e.g., blood cost/ acute discharge, RBC/1000 pt. days, Platelets/ acute discharge)
  • Report includes 50th, 75th,, and 90th percentile comparison to provide range of opportunity
  • Clinical and financial opportunities identified and quantified